Two terms that appear in almost every substantive description of a biotech company’s drug development program are drug target and biomarker. They are related but distinct — and confusing the two is one of the most common sources of misinterpretation when retail investors read clinical trial descriptions, pipeline summaries, or drug mechanism explanations. Understanding the difference between what a drug acts on and what a test measures — and how the two work together to design and interpret clinical trials — is foundational knowledge for evaluating modern precision medicine programs.
The Short Answer
| A drug target is the specific biological molecule — typically a protein, receptor, or enzyme — that a drug is designed to interact with to produce its therapeutic effect. A biomarker is a measurable biological characteristic — a protein level, genetic mutation, gene expression pattern, or imaging finding — that provides information about normal biological processes, disease processes, or responses to treatment. The drug target is what the drug acts on; a biomarker can be used to select patients likely to respond (predictive biomarker), measure whether the drug is hitting its target (pharmacodynamic biomarker), or evaluate whether a patient is responding to treatment (response biomarker). |
From Population Medicine to Precision Medicine
For most of pharmaceutical history, drugs were evaluated in broad patient populations — everyone with the same diagnosis received the same treatment and the benefit was measured as an average across the group. This population-level approach produced many effective drugs, but also obscured the reality that in many diseases, particularly cancer, different patients with the same diagnosis can have fundamentally different molecular drivers of their disease, and the same drug can be highly effective in some patients and entirely inactive in others.
The shift to precision medicine — treating patients based on the specific molecular characteristics of their disease rather than their diagnosis alone — was accelerated by the sequencing of the human genome and the development of technologies to rapidly characterize the molecular profile of individual tumors. Imatinib (Gleevec) is often cited as the paradigm: it targets the BCR-ABL fusion protein produced specifically by the chromosomal translocation that drives chronic myeloid leukemia, and is effective only in patients whose cancer is driven by that specific mutation. The drug and the biomarker (BCR-ABL) are inseparable in clinical practice.
Types of Biomarkers and What Each Measures
Predictive biomarkers identify patients who are more likely to respond to a specific treatment. HER2 overexpression in breast cancer is a predictive biomarker for HER2-targeted therapies like trastuzumab and pertuzumab. PD-L1 expression is a predictive biomarker for checkpoint inhibitor immunotherapy in multiple cancer types. In clinical trial design, a predictive biomarker is used to enrich the study population — enrolling only patients whose tumors express the relevant marker — increasing the probability of detecting a treatment effect.
Pharmacodynamic biomarkers measure whether the drug is hitting its intended target — they confirm target engagement in vivo. If a kinase inhibitor is designed to block phosphorylation of a specific protein, a blood or tumor sample showing reduced phosphorylation at the target site is a pharmacodynamic biomarker demonstrating that the drug is working as intended at the molecular level. Pharmacodynamic data is highly valued in early Phase 1 trials as evidence that the drug is biologically active in humans, even before efficacy endpoints are measurable.
Prognostic biomarkers measure disease severity or natural history, independent of treatment. They tell you something about how a patient’s disease is likely to progress, regardless of which treatment they receive. Prognostic biomarkers are clinically important but are often confused with predictive biomarkers; the distinction is that a predictive biomarker predicts response to a specific treatment, while a prognostic biomarker predicts disease course in general.
Companion Diagnostics — When the Biomarker Becomes Part of the Drug Approval
A companion diagnostic is a laboratory test that is required to be used alongside a specific drug — the drug is approved with a label requirement that the patient must test positive for the relevant biomarker before receiving the treatment. The companion diagnostic is co-developed with the drug and reviewed by the FDA as part of the drug approval package.
The FDA requires a companion diagnostic when the drug is effective only in — or has significant safety risks specific to — patients with a particular biomarker status. Trastuzumab (Herceptin) cannot be prescribed for breast cancer without first testing for HER2 overexpression. Pembrolizumab (Keytruda) in certain indications requires testing for PD-L1 expression or microsatellite instability. For investors, a drug with a companion diagnostic has a more precisely defined patient population — which can limit the addressable market but also improve the probability of trial success by ensuring only likely responders are enrolled.
Why Biomarker Strategy Affects Clinical Trial Risk
Biomarker-driven clinical trials — which enroll only patients who test positive for a specific molecular marker — have historically shown higher success rates than unselected trials, precisely because they enroll the patient population most likely to respond to the treatment. A well-designed biomarker strategy can be the difference between a Phase 3 trial that succeeds and one that fails because the treatment effect is diluted by a large proportion of non-responding patients in an unselected population.
The risk for investors is that a biomarker-restricted drug has a smaller addressable market. A drug approved only for HER2-positive breast cancer (approximately 15–20% of all breast cancer patients) has a smaller commercial ceiling than a drug approved for all breast cancer patients. Biomarker strategy is a fundamental commercial as well as clinical decision, and investors should understand both dimensions when evaluating a biomarker-driven program.
What This Does Not Guarantee
| A strong predictive biomarker hypothesis does not guarantee clinical success. The association between a biomarker and drug response identified in early trials sometimes fails to hold in larger, more diverse patient populations. Companion diagnostic development adds complexity to the regulatory and commercial pathway — the diagnostic test must be validated, manufactured, and approved alongside the drug. And biomarker-restricted patient populations, while improving trial success probability, can limit the commercial opportunity in ways that affect the ultimate investment return. |
Key Takeaways
- A drug target is the biological molecule the drug is designed to act on; a biomarker is a measurable biological characteristic used to select patients, confirm target engagement, or assess response
- Predictive biomarkers identify patients likely to respond to treatment; pharmacodynamic biomarkers confirm the drug is hitting its target; prognostic biomarkers predict disease course independent of treatment
- Companion diagnostics are required FDA-approved tests that must be used with a specific drug — they co-develop with the drug and restrict prescribing to patients with the relevant biomarker status
- Imatinib (Gleevec) and BCR-ABL is the paradigm case for target-biomarker integration in precision oncology
- Biomarker-enriched trials have historically higher success rates than unselected trials because they enroll populations most likely to respond
- Biomarker restriction narrows the addressable market — a clinical benefit but a commercial constraint that investors must factor into revenue projections
- A predictive biomarker hypothesis established in early trials does not always hold in large, diverse Phase 3 populations — clinical validation is required
Sources
1. FDA — Companion Diagnostics: https://www.fda.gov/medical-devices/in-vitro-diagnostics/companion-diagnostics
2. NIH — Biomarkers: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3078627/
3. NCI — Biomarkers in Cancer Research: https://www.cancer.gov/about-cancer/treatment/research/biomarkers
4. FDA — Precision Medicine: https://www.fda.gov/patients/precision-medicine
Disclaimer
This article is based on publicly available regulatory information, company filings, and authoritative industry sources. All information was current as of the date of publication. BioTech Stocks Daily has not received compensation from any company referenced in this article in connection with this coverage.
This article contains references to forward-looking statements and clinical projections. Forward-looking statements involve known and unknown risks and uncertainties, and actual results may differ materially from those projected. Past clinical results do not guarantee future outcomes.
The information provided in this article is for informational and educational purposes only and does not constitute financial, investment, or medical advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making any investment decision.
For full terms, see our Disclaimer.
